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ABSTRACT 
 
Full Name : ALI OSMAN SAEED ALTOUM 
Thesis Title : Synthesis and characterization of some platinum(II) complexes with 
selone ligands and their anticancer activity 
Major Field : Chemistry 
Date of Degree : April 2016 
 
Despite the wide application of cisplatin as a chemotherapeutic agent, cisplatin exhibits 
severe side effects which limit the possibilities for gaining therapeutic benefits from dose 
intensification. Therefore, there is a need for new Pt(II) compounds that would have able 
enhance clinical effectiveness and eliminate the toxicity. In this study, two series of 
platinum complexes with some selone ligands have been synthesized and characterized 
by elemental analysis, infrared spectroscopy FTIR mid and far, nuclear magnetic 
resonance NMR (
1
H,
13
C,
77
Se and 
195
Pt  solution NMR) as well as 
13
C solid state NMR 
and single crystal X-ray crystallography. The general formulas for these complexes are 
trans-[Pt(selone)2Cl2] and ionic species which is [Pt(selone)4]Cl2. The spectroscopic 
methods confirm that the Pt(II) ion coordinate to selone ligands through selenium donor 
atoms not via nitrogen atoms. The X-ray structures for complexes [Pt(EtImSe)4]Cl2 (B5)  
and [Pt(iso-prImSe)4]Cl2 (B7), were showed that the platinum atom is bounded to four 
selenium atoms; each atom belonging to selone ligand in a distorted square planar 
geometry. The synthesized complexes (A1-A7) were screened for anticancer activity, and 
the results showed that the new compounds exhibit significant activities against HeLa 
(human cervical cancer) and MCF7 (human breast cancer) cell lines. 
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 ملخص الرسالة
 علي عثمان سعيد التوم :الاسم الكامل
 للسرطان.  ) مع بعض مترابطات السيلون ونشاطيتها كمضاداتIIو توصيف معقدات البلاتين(تخليق  :عنوان الرسالة
 التخصص: كيمياء
  6102مايو  :تاريخ الدرجة العلمية
التطبيقات الواسعه للسيسبلاتين كعامل علاج كيميائي،سيسبلاتين يظهر اثار جانبية حادة تحد من علي الرغم من  
جديدة لديها   II(ن (بلاتيال امكانية الحصول علي الفوائد العلاجية من تكثيف الجرعة لذلك هنالك حوجة ماسة لمركبات
دراسة، تم تخليق سلسلة من معقدات البلاتين مع بعض قدرة عالية لتعزيز الفعالية السريرة و ازالة السمية. في هذه ال
مترابطات السيلون و وصفت باستخدام التحليل العنصري، مطيافية الاشعة تحت الحمراء المتوسطة و البعيدة، الرنين 
 الصيغ العامةالنووي المغنطيسي، فضلا عن الرنين المغناطيسي النووي للحالة الصلبة و الاشعة السينية للبلورات. 
   2lC]4)enoles(tP[ .  والانواع الايونيه هي   ]2)lC2)enoles(tP[ -snartي لهذه المعقدات ه
الطرق الطيفية اكدت ان ايون البلاتين ارتبط بمترابطات السيلون عبرذرة السلينيوم المانحة لا عن طريق النتروجين. 
عة ذرات سلينيوم كل ذرة منتمية لمترابط السيلون هياكل الاشعة السينية لمعقدات اظهرت ان ذرة البلاتين محاطة بارب
) 5Bوضحت الاشعة السينية ان  ذرة البلاتين للمعقدات  ( الحر في شكل رباعي السطوح المشوه.
ذرات سلينيوم وكل ذرة منتميه  باربع مرتبطة  2lC]4)eSmIrp-osi(tP[  )  7Bو (  2lC]4)eSmItE(tP[
تم فحص نشاطيتها     7Aالي  1A لمترابطات السيلون في شكل رباعي سطوح مشوه. المعقدات المخلقة من 
) و aLeH( الرحمكمضادات  للسرطان، وضحت  النتائج ان المركبات الجديدة اظهرت نشاطية عالية  ضد سرطاني  
 ) .7-FCMالثدي(
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CHAPTER 1 
Introduction 
1.1 Historical background 
Cisplatin cis-[PtCl2(NH3)2], (CDD) is one of the widely used anticancer agent, it has been 
investigated for the last 40 years, nevertheless it is known for approximately 150 years 
ago [1- 2]. The biological activity of cisplatin was unnoticed until the 1960 [2]. This 
discovery started from unrelated electromagnetic cell division experiments carried out by 
Barnett Rosenberg. He observed that platinum chloride complexes were unintentionally 
generated in situ from platinum electrodes and resulted in filamentous growth of E.coli 
cultures [3-5]. The clinical trials of cisplatin began in 1971 [6]. The trials showed that 
cisplatin was extremely effective in the treatment of solid tumors of genitourinary and 
gynecologic regions [7-10], in addition to the head, neck and lungs tumors [11]. Further 
clinical trials have shown cisplatin to be extremely effective in the treatment of advanced 
testicular and ovarian cancer [12-14].  In the past 15 years, the use of cisplatin has 
expanded rapidly and now it considered as one of the most widely used as anticancer 
drugs [12]. Previously, the long term cure rate for testicular cancer was only less than 
10%. But now cisplatin drug has raised the long term survival rate to more than 80% 
[15]. However, its clinical use diminished by severe side effects such as nephrotoxicity 
[16], neurotoxicity, ototoxicity, nausea, vomiting and gastrointestinal effects [17]. 
Moreover, it’s also diminished by inherent and acquired tumor resistance to the drug 
[15]. 
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These limitations led to the preparation of new platinum(II) complexes such as 
carboplatin and oxaliplatin. It has been found that all platinum(II) complexes share one 
common structure which is the coordination of two amino groups (bearing at least NH) 
and two leaving groups such as chloride, citrate or oxalate [18-19], they connect to the 
DNA via N7  of two adjacent (G) Guanine atoms with Pt(II) center atom through  
intrastrand cross-link [20]. 
1.2 Statement of the problem 
The anticancer activity of cisplatin is attributed to the interaction between (CDD) and the 
genomic DNA; this binding may suppress the DNA reproduction mechanism and lead to 
the death of tumor cell. Unfortunately, once cisplatin administered intravenously to the 
patient body, there are many possibilities for binding with the biomolecules in form of 
proteins, enzymes and peptides such as selenodiglutathione (GS-Se-SG) and 
selenoproteins (Figure 1) [21]. The interaction between Pt(II) complexes and these types 
of biomolecules will lead to form selenols [16, 22], and this prompting inactivation of an 
incredible measure of cisplatin compounds which are directly responsible about the 
toxicity occurrence, Moreover, binding of cisplatin to these molecules is responsible of 
the severe side effects of pharmacological properties that include some toxicity and 
resistance development [23].  
On the other hand, it can be said that the great effectiveness of the Pt(II) complexes as 
anticancer agent is referred to the binding of the Pt metal with nitrogen containing 
biomolecules such as amino acid or nitrogen donor in DNA. 
Many platinum complexes with thione ligands have been already synthesized, and most 
of them show higher cytotoxicity relative to cisplatin [24-26]. This success of thione 
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platinum(II) complexes in cancer treatment was encouraged us to synthesized a series of 
analogue selones platinum(II) complexes. So it is expected that these complexes have 
good anticancer activities. 
 
Figure 1: Chemical structues of Selenocysteine, Selenocystamine and 
Selenodiglutathione(GS-Se-SG). 
1.3 Aims of the study 
Selenium complexes suppress tumor growth [21]. The selenium complexes are develop 
gradually as anticancer agent (chemotherapeutic agents) through cancer cell selectivity 
and many targets response, which are lead to improve in inhibiting development of 
resistant of the cancer drugs. In addition to that, any ligands containing selenium such as 
selones and selenolates are attend to produce stable complexes form with metal ions class 
B (soft) [27], which attributed to selenium is considered to be a soft Lewis base. 
Moreover, the binding between them in the body will lead to reduce the toxicity of the 
selones and platinum metal [28-29]. The reactions of selone ligands with transition 
metals have been well studied. Complexes of Ag(I) [30-31], Au(I) [32-33], Cd(II) [34] 
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and Hg(II) [35], have synthesized in recent years in finding simple model compounds for 
metalloproteins. It is surprising that analogous Pt(II) with selones complexes have not got 
much consideration. So in this work, some new Pt(II) complexes have been prepared with 
general formula [PtCl2L2] in case of 1:2 M: L ratio or [PtL4]Cl2 in case of 1:4 M: L ratio 
where M is Pt(II) central ion and L represents selone ligands as shown in Figure 2. 
Synthesized compounds were successfully characterized using various physical methods 
such as multinuclear NMR (
1
H, 
13
C and 
77
Se), Elemental analyzer (EA), Infrared 
spectroscopy (Mid and Far IR) as well as single crystal (XRD). The anticancer activity of 
synthesized complexes has been evaluated using model cancer cell lines. 
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Figure 2: Structures of selone ligands 
a) (SeU), Selenourea(CH4N2Se)  
b) “(ImSe), R = R/ = H; Imidazolidine-2-selone. 
c)  (EtImSe), R= C2H5, R/ = H; N-ethylimidazolidine-2- selone. 
d) (N-PrIMSe), R= C3H7, R/ = H; N-propylimidazolidine-2- selone. 
e) (i-PrImSe),  R= i-C3H7, R/ = H; N-(i-propyl)imidazolidine-2- selone. 
f) (DiazSe), 1,3-Diazinane-2- selone. 
g)  (DiapSe), 1,3-Diazipane-2- selone.”   
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1.4 Objectives 
The main objectives are: 
 
1. Study the reaction of K2PtCl4 with a series of Selenium containing ligands (L) in 
1:2 ratio to synthesize complexes with general formula [PtL2Cl2].  
2. Study the reaction of K2PtCl4 with a series of Selenium containing ligands (L) in 
1:4 ratio to synthesize complexes with general formula [PtL4]Cl2.  
3. Characterize the above synthesized complexes by some techniques such as: 
elemental analysis, FT-IR spectroscopy, 
1
H NMR, 
13
C and 
77
Se NMR solution, 
13
C solid state NMR and single crystal X-Ray crystallography.  
4. Examine the biological efficiency of these new complexes in vitro against some 
human cancer cell lines compared to parent complex cisplatin and carboplatin as 
controls. 
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CHAPTER 2 
Literature review  
 
2.1 Applications of Metals in Medicine 
The application of inorganic metals in medicinal field has been known for thousands 
years ago [36]. As a one of the famous metals, mercury was used for the treatment of 
syphilis during the European epidemic in the 15th and 16th centuries [36]. In addition, in 
1909, Erich was introduced the arsenic compound Salvarsan, as a cure for syphilis too 
[37].  By the middle of the last century, great expansion in the application of metals in 
medicine was made hence the technetium and the platinum metals were introduced to this 
field. C. Perrier and E. Serge discovered technetium in 1937, by neutron capture in 
molybdenum ores. Within the end of the past century, technetium attracts much interest 
because of its important contribution to the diagnostic medicine. The platinum metal as 
well known in medicine as an anticancer drug, this fact started at the time of the great 
discovery made by Barnett Rosenberg, he was trying to find whether there is a 
contribution of magnetic or electronic dipole fields on cell division by applying 
electromagnetic radiation on mammalian and bacterial cells [3]. Recently, cisplatin is the 
widest compounds used as anticancer drugs [4]. This is due to its activity against cervical, 
bladder, ovarian, neck and head, lung and testicular cell cancers [15]. Despite the above 
mentioned fact, cisplatin is not effective in other forms of cancers for examples, renal, 
leukemia and gastrointestinal cancers [38]. 
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2.2 Cancer Disease and Cancer Therapy 
Cancer is a worldwide well-known disease caused by body cells, which become 
abnormal, and divides without control and can attack other normal tissues. Cancer cells 
could spread through the blood stream and lymph systems to other parts of the body. 
Inevitably, the tumor burden will bring the death, frequently by physically blocking or 
packing veins or organs, for example, the brain [38]. Cancers are of two types- malignant 
tumors and benign tumors. Malignant tumors are different from benign tumors as they 
show uncontrollable growth, invade locally, and metastasize to distant body parts, they 
named according to the type of cell or organ in which they start such as breast cancer, 
lung cancer, colon cancer. Benign tumors grow in one place and lack the ability to 
metastasize [39-40]. 
Cancer is brought by both, internal factors like hormones, inherited immune conditions 
and mutations or acquired/environmental factors such as radiation, diet, tobacco and 
infectious organisms [41]. 
Many methods was introduced for cancer treatment, it can be used alone or in 
combination including surgery, biological therapy, hormone therapy, immunotherapy, 
radiation, gene therapy and chemotherapy. Unfortunately, these treatments dose not 
totally help the patients, they may not give good treatment at all, or just increase the time 
of survival [36].  The chemotherapeutic drugs aim to kill malignant tumor cells through 
inhibiting their cellular division, but there are just a small number of subgroups that can 
benefit from the effective targeted therapies, which have been noted that the development 
of cancer chemotherapy is a very difficult task to achieve [42]. The most difficult 
problems found in cancer chemotherapy are the nonspecific toxicity due to the spread out 
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of the drug throughout the body, which requires large dose of the pharmaceuticals to 
achieve high concentrations at a local tumor [43]. Another problem in cancer 
chemotherapy is raised from drug resistance, which could be defined as the ability of 
cancer cells to resist different drugs [44]. There are different ways by which cancer cells 
can evade the chemotherapy. This resistance exists against all kinds of drugs, even the 
newly applied ones. Therefore, it is necessary to circumvent drug resistance to improve 
the chemotherapy [45]. The major problem that facing the development of a new 
anticancer chemotherapy is the big gap between the promising findings in preclinical in 
vivo and in vitro models and the real clinical results obtained in the complex therapeutic 
situation of cancer in patients [42].   
2.3 Platinum based drugs for cancer therapy 
The most well-known platinum compounds cisplatin is successfully used in 
chemotherapeutic indicated considerable activity toward some of the cancer cell lines, it 
was synthesized in 1844 by Michel Peyrone and named as Peyrone chloride [46], and in 
1893 Alfred Warrner deduced the structure of cisplatin. Its biological activity was 
discovered by accident in 1960 by biophysicist Barnett Rosenberg at University of 
Michigan, United States [46]. 
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Figure 3: Isomeric structure of diammine dichlorido platinum(II) complex, A is Cisplatin 
and B is Transplatin. 
 
Initially, he designed to study whether magnetic or electric dipole fields contribute to cell 
division, by applying electromagnetic radiation on mammalian and bacterial cells. 
Without intention, a group of platinum electrodes which is known not latent was included 
in the development load of Escherichia coli in NH4Cl buffer [47]. After the 
electromagnetic field turned on, the filamenation occurs which is a strange growth of the 
bacteria length; reached up to 300 times of the normal length. This phenomenon could 
not be attributed to the effect of the applied field. Investigations found that the 
observation is due to the presence of platinum(II) and platinum(IV) ammine chlorido 
complexes formed in situ originating from electrolysis at the platinum electrodes. Further 
investigations showed that specifically, cis-diammine dichlorido platinum(II) is the 
causing molecule of these biological effects [48]. 
Several medicinal trials of cisplatin as a drug commenced soon thereafter, and it was used 
to treat first patient in 1971 [49]. Cisplatin was granted approval against several human 
cancers in 1978 by (FDA) United States for food and drug administration [49]. Recently, 
cisplatin is considered to be the first compound widely used as anticancer agents [23, 50]. 
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This is due to its activity against a lot of cancer cells like cervical, bladder, neck and 
head, ovarian, testicular and lung cancers cells. 
 In spite of the mentioned advantages, the first platinum generation compounds (cisplatin) 
is not effective as drug for treating of some others tumors such as renal, leukemia and 
gastrointestinal cancers [51]. 
In general, it was believed that the relationship between structure and activity of platinum 
drugs to possess cis geometry, platinum atom should bind via amine ligands (bidentate 
ligands) or through the two amines and the two good leaving groups with an intermediate 
binding strength such as chloride, sulfate, Oxalate and citrate until Farrel and his group 
reported that platinum complexes with trans configuration also showed antitumor 
activity. Examples of such biologically active trans platinum compounds include trans-
[PtCl2(iminoether)2] and trans-[PtCl2{NH2CH(CH3)2}{NH-(CH3)2}]  [52]. 
2.3.1 Cisplatin mechanism of Action 
It has been noted that cisplatin becomes activated inside the cellular system before it 
reach its target of DNA through the equation mechanism (one of the chlorides is replaced 
by water) (Figure 4).  Followed by formation of DNA adducts (Figure 5). Several studies 
conducted in vitro indicated platinum coordinating to DNA through N7 of the purine 
bases of guanine (G), and to a lesser degree, adenine (A) to produce different type of  
platinum- DNA adducts, such as GpG 1,2 intrastrand (60–65 percent  of the total adducts) 
through binding of platinum complex to two adjacent guanine (G) of the same DNA 
strand, or ApG 1,2 intrastrand (20–25% of all adducts) through binding of platinum to 
two adjacent nucleobases; adenine (A) and guanine (G) of same DNA strand. There are 
also less frequent adducts which arise through binding to different DNA strands [53]. 
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These adducts are the key to the success of the drug in programmed cell death (apoptosis) 
[50, 54]. 
 
 
 
Figure 4: Cisplatin undergoes spontaneous hydrolysis in aqueous solutions 
It’s believed that the N7 position of the imidazole rings in the DNA purine bases guanine 
and adenine is most nucleophic and accessible site, which can be a major target to 
interact with cisplatin, mainly through [1,2-d(ApG) or 1, 2-d(GpG) intrastrand cross-
links]. it was found that N7 of guanine thermodynamically  and kinetically favorable site 
for binding that leads to resolve of DNA [52]. 
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Figure 5: The main products produced from the cisplatin and DNA interaction. 
a) is [1, 2-d(GpG) interstrand cross-link], b) is [1, 2-d(GpG) intrastrand cross-link], 
c) is [1, 3-d(GpG) intrastrand cross-link], d) is [protein-DNA adduct]. 
 
Figure 6: Guanine and Adenine structure, A. guanine, B. Adenine. 
When the platinum binding to the nucleophilic site in the two  structures form, the amine 
ligands (NH3) act as donor hydrogen-bonding, while C6 position in (amino group) of 
adenine ring and (oxo group) of  guanine ring, known to be  hydrogen-bond acceptors. 
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Hydrogen bond between the N-H….O=C6 in case of guanine is much better than the 
hydrogen bond forms between the N-H….NH2-C6 in case of adenine. In addition, strong 
interaction is identified for guanine compared to adenine using MO analysis [55]. 
To insure that the N7 for guanine is preferable site for platination over adenine, Lippard 
and his group used density functional theory (DFT) to study the interaction  of [Pt 
(NH3)2]
2+
 complexes with guanine and adenine. Thermodynamics and kinetics factors of 
the complexes were taken into account, verifying that of guanine is more reactive 20 
times than adenine toward platination [56]. 
 
Figure 7: Hydrogen bonding in case of guanine and adenine after platination. 
2.3.2 DNA-Repair 
DNA-repair formed by four major pathways including (NER) nucleotide-excision repair, 
(MMR) mismatch repair, double-strand-break repair, and (BER) base-excision repair, but 
NER considered as the major pathway used to eliminate cisplatin lesions from DNA [16]. 
2.3.3 Resistance of Tumors to Cisplatin 
The resistance of tumors to cisplatin attracted the attention of scientists to study how 
tumor resistance was made amid courses of chemotherapy with these anticancer 
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medications, and why a portion of alternate tumors were safe. Conventionally, some 
studies were keen on the explanation for the excessive touchiness of testicular tumor to 
cisplatin. These investigations concluded that, there might be two reasons for the above 
mentioned tumor resistance: initial, a disappointment of an adequate amount of cisplatin 
to reach the DNA target or an inability to accomplish cell death after platination process 
occurs [57]. 
2.3.4 Resistance through Insufficient DNA Binding 
For many years, it has been reported that, in many cells' tumor resistance acquired 
through the course of cisplatin administration that is a reduction of platinum 
concentration accumulated in the cells in comparison to that of the parental cells [50]. 
However, until present, the exact molecular mechanism by which the anticancer drug 
enters the cells remained unclear. The uptake of cisplatin is affected by several factors 
[58], like pH, sodium and potassium ion concentrations, and the presence of reducing 
agents; and the way that it transports by transporters or through gated channels 
hypothesized in addition to passive diffusion (Figure 9). The major plasma-membrane 
transporter, copper transporter-1 (CTR1), which has an essential role in copper 
homeostasis, was found to be involved in cisplatin influx, the loss of CTR1 has led to 
increase in drug resistance even high in concentrations of cisplatin [59]. Besides, there is 
many of evidences that the high concentration of sulfur containing species, such as 
metallothioneins [60], and glutathione [61], which are rich in the sulfur-containing amino 
acids, methionine and cysteine, will lead to detoxification and there for resistance to 
cisplatin because platinum prefer to bind to sulfur insatiably [59]. 
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2.3.5 Resistance mediated after DNA binding 
The acquired resistance to cisplatin could also occur after the formation of platinum–
DNA adducts, through cellular survival by either removal or tolerance of DNA damage 
[62].  The enhance sensitivity of testicular cancer to cisplatin was found to be a result 
from DNA-repair deficiency. On the other hand, there are many types of cisplatin-
resistant cell lines have been shown to have tumor drug resistance because of the increase 
in the DNA-repair capacity [63].  
 
Figure 8: The interaction of activated cisplatin with biomolecules before reaching DNA 
of the cells. 
2.3.6 The Side Effects of Cisplatin 
Cisplatin as an anticancer agent is commonly used in solid tumors treatment, but it lacks 
the selectivity for tumor cells, which induce severe side effects such as gastrointestinal 
toxicity, bone-marrow suppression, ototoxicity, neuropathy, and nephrotoxicity. The 
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latest one is the main effect that hampers the use of cisplatin in the therapeutic process 
[64-65]. Several studies found that 25% of patients might develop reversible azotemia 
after receiving a single dose of cisplatin [66]. Besides, irreversible kidney failure also 
may occur at large doses, or with frequent cycles of treatment [67]. Nephrotoxicity 
induced by a complex process involves severe cytotoxic effects on tubular epithelial cells 
that reduce the tubular epithelial cells via apoptosis, and necrosis, followed by fibro 
proliferative changes and inflammatory cell infiltration [68].   
Cisplatin partially inhibits the protein synthesis in the tubular epithelial cells, and disrupts 
the cellular antioxidant defense system (i.e., glutathione, GSH), resulting in DNA damage 
and lipid peroxidation. Glutathione, (GSH) could be administered to alter the 
nephrotoxicity induced by cisplatin [69], without affecting its antitumor activities [70].   
2.4 Carboplatin 
Carboplatin has been known as a second generation of cis-diammine(cyclobutane-1,1-
dicarboxylato) platinum(II), that differs from cisplatin by the presence of a bidentate 
dicarboxylate ligand as leaving group instead of the more labile cisplatin’s chlorides. It 
was discovered in the early 1970s by Rosenberg and his group to improve the 
performance of the first generation cisplatin and to expand the range of useful anticancer 
activity [71]. By 1989, carboplatin was approved as drug under the brand name 
paraplatin. Carboplatin has slower substitution rate compared to cisplatin, this feature 
makes it much less chemically reactive (ototoxic, neurotoxic, and nephrotoxic) in 
contrast with cisplatin and can be administrate in a higher measurement than cisplatin, 
this brief scientists to concentrate on instruments by which the compound can be initiated 
in vivo. When it going through the blood, carboplatin shows to enter the cell through 
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inactive dissemination, in spite of the fact that it may enter by means of dynamic 
transport or through particle channels. Osella and collaborators recommends that 
carboplatin enter the cell through an aloof dispersion mechanism [72]. 
The lower toxicity of carboplatin has been the point of preference that empowered it to 
get overall endorsement for clinical use. Shockingly, it's still just dynamic in the same 
scope of tumors as cisplatin is still managed intravenously [73] and  possess similar 
structure as cisplatin that can bind form DNA adducts as cisplatin and can’t be overcome. 
Therefore, the researchers focused for seeking on a new platinum compounds with 
improved tolerability profiles that may overcome the side effect of the first generation. 
 
 
 
2.5 Oxaliplatin 
The third generation of  platinum(II) complex (([(1R,2R)-cyclohexane-1,2-diamine]- 
(ethanedioato-O,O′)platinum(II), is called oxaliplatin, which contain a rigid bidentate 1,2-
diaminocyclohexane as stable ligand (instead of the  monodentate of NH3 ligands) and an 
oxalate leaving group, it was approved in 2002, under the name Eloxatin.  Inclusion of 
Figure 9: Chemical structure of [cis-diammine(cyclobutane-1,1-dicarboxylato) platinum(II)] 
(Carboplatin). 
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the rigid moiety diaminocyclohexane was intended to contribute to a larger cytotoxicity 
when compared to the first and second generation (more damaging Pt-DNA adducts), as 
well as to overcome cross resistance with those widely used drugs, the particularly high 
activity of this third-generation agent, even in cisplatin-resistant tumor models, coupled 
to its decreased toxicity, prompted further studies on its use as a treatment option after the 
failure of the cisplatin or carboplatin therapy [58]. 
 
 
2.6 The importance of selenium 
The effect of selenium compounds on biological systems has been a great interest to 
researchers. Although selenium is toxic if taken in high doses, it is an essential trace 
element and natural ingredient of diets, is claimed to have the capability to become anti-
carcinogenic, a claim supported by considerable evidence. In addition, the positive results 
of the recently conducted clinical experiments [74–77] prompt this outcome, especially 
when accompanied with similar evidence of studies from epidemiology, mechanistic 
research, and experimental animal. It suggests that Se can tackle cancer threat in two 
different ways: the first as a main source for many selenium enzymes with functions of 
antioxidant and redox-regulatory, and the second as a supplier of antitumorigenic 
selenium metabolites [78–80]. The first way could be seen much more relevant to cancer 
Figure 10: Oxaliplatin, [(1R, 2R)-cyclohexane-1,2-diamine]- (ethanedioato-
O,O′)platinum(II). 
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prevention from beginning, while the other to cancer suppression.  But it could be also  
that supra-nutritional amount of selenium, through modifying tissue level selenium 
shortages, could stop transformed cells through a group of effects, including selenium 
metabolites’ anticancer activities and selenium protein activities as well [76]. 
2.7 Selenium antitumorigenesis Mechanisms   
Based on this, it could be expected for selenium’s anticarcinogenic effects to change with 
the amount and way of its delivery, and with the recipient’s selenium condition. 
Therefore, people with selenium shortage might appear to take the advantages of 
additional selenium dependent glutathione peroxidases and thioredoxin reductases, which 
work against cancer inception through protecting against reactive oxygen species.     
Meanwhile, people who are selenium sufficient, on the other hand, might be taking the 
advantages of its supra-nutritional does that increasingly produce selenium metabolites, 
which in turn have the capabilities to improve the observation of the immune system, 
change carcinogen metabolism, prevent proliferation of cells, boost apoptosis and inhibit 
tumor neo-angiogenesis [81]. As indicated by evidence, some specific selenium 
metabolites could tackle these anticarcinogenic effects, such as hydrogen selenide [82–
84], methylselenol [85–90] and selenodiglutathione in people who are exposed to 
selenate or selenite [91–96]. In animal model, these effects have been constantly linked to 
selenium intakes equivalent to a minimum of tenfold the amount needed to prevent 
clinical symptoms of selenium shortage. On a basis of unit body weight (around 100 μg/
kg rodents body weight), they are much larger than what most people around the world 
are exposed to, which is going to be below 100 μg/day. Since the selenium proteins 
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seem to be exciting in its highest level in animal tissues at dietary levels not 
exceeding 0.5 μg Se/Kg, there has been a current conception that the anticarcinogenic 
effects caused by such levels of selenium are probably not associated with selenium 
protein [91]. 
2.8 Selenourea and its derivatives (selones) 
Thione compounds have shown many pharmacological benefits [97]. Thiourea, 1,3-
imidazolidine-2-thiones and their derivatives are an interesting class of ligands, they 
possess ambidentate nature. They have been used for a long time as antifungal agents, 
protecting agent against side effects of kidney during administration of cisplatin, and as 
anti-HIV. The reactions of thione ligands with transition metals have been well studied in 
order to find simple model compounds for metalloproteins [98]. However, the analogous 
complexes containing selone ligands doesn’t receive any attention, may give a better 
result if they coordinated with platinum(II) ion. Although, Devillanova and his team have 
reported the preparation of the (ImSe) with Cd(II), Hg(II) and Zn(II) complexes. And 
also Saeed Ahmed and his team workers have investigated these ligands with Ag(I), 
Au(I) and Cd(II) [34,35 and 40]. 
Selone ligands can bind to platinum ion via selenium or nitrogen atoms. These complexes 
may exist in a selenol 
_
 selone equilibrium see Figure 12. However, it has been 
established that the selenone form dominates in the solid state of these complexes [99]. 
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Figure 11: Resonance and tautomerism structure of selenourea (selenol – selone 
equilibrium). 
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CHAPTER 3 
Experimental work 
3.1 Chemical Materials 
Potassium tetrachloroplatinate(II) was obtained from “Strem Chemicals,In. All the 
Selone ligands (Figure 2) are prepared according to the procedure that described in the 
literature
 
[100-101]. The NMR solvents were purchased from Sigma-Aldrich Chemical 
Co. While the other solvents were collected from Fluka Chemical Co.” and these 
materials handled without any further purification. 
3.2 Instrumentations 
3.2.1 Elemental Analysis 
Elemental analysis of carbon, hydrogen and nitrogen of the synthesized complexes has 
been done using CHNs Elemental Analyzer (EA). 
3.2.2 Melting Points 
Melting points of the synthesized complexes were made on Electro thermal apparatus and 
are uncorrected. 
3.2.3 Infrared Spectroscopy Measurements 
The all FT- IR data of the synthesized Platinum(II) compounds and their original selone 
ligands were carried out on 180 spectrophotometer (Perkin–Elmer Fourier transform 
infrared spectroscopy) using solid KBr pellets in the window from 400 to 4000 cm
-1
. 
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3.2.4 
1
H NMR Measurements 
The 
1
H NMR spectra were conducted on a (Jeol JNM-LA 500) NMR spectrophotometer 
at room temperature, at a frequency of 500 MHz under conditions 32 K data points, 1.50 
s pulse dely, and 45
◦
  pulse angle. 
3.2.5 
13
C NMR Measurements 
The spectra of 
13
C nuclear magnetic resonance have been performed at 500 MHz under 
conditions 32 K data points with 
1
H broadband decoupling at 297 K. And 0.963 
acquisition time, 3.2 s pulse delay and a 5.75µs pulse width for 
1
H NMR and 2.5 s pulse 
delay and a 5.12µs pulse width for 
13
C NMR. All the 
13
C NMR data were measured 
relative to external reference Tetramethylsilane (TMS). 
3.2.6 
13
C Solids NMR Measurements 
13
C solid state NMR spectra have been done on a “JEOL LAMBDA 500 spectrometer at 
125.65 MHz (11.74 T)” operating frequency, at room temperature. Our synthesized 
complexes were pressed into 6mm of rotors of zirconium oxide tubs. High power 
decoupling and solid state cross polarization were applied. Using contact time of 5.0 ms 
and pulse delay of 7.0 s in the CPMAS experiments. Using magic angle spinning range 
between 2000 Hz to 4000 Hz. 
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3.2.7 
77
Se NMR Measurements 
77
Se NMR spectra for the selone ligands and their relative Pt(II) species were recorded 
using (NaHSeO3 in D2O) as external reference at 1308.00 ppm, using 95.35 MHz, 0.311 s 
acquisition time and using a 2.00 s as pulse delay. 
3.3 Synthesis of Compounds 
3.3.1 Synthesis of Selone Ligands 
Selenourea was prepared from Thiourea by converting it to S-methylthiouronium iodide 
using methyl iodid and then an aqueous NaHSe solution was added to S-
methylthiouronium iodide.The desired product was obtained and recrystallized from 
ethanol [100-101]. 
3.3.2 Synthesis of [PtL2Cl2] complexes 
Due to the easy decomposition of the free selones ligand in air, these complexes were 
synthesized by dissolved (1mmol) of selone ligands in methanol solvent added to 
(0.5mmol) of Potassium tetracholoropaltinate(II) which dissolved in a hot acetonitrile. 
Then the mixture solutions were stirred for 1hour under nitrogen in a dry box using 
anhydrous deairated solvents, colored precipitate were formed after filtration process 
were sufficiently stable to be handled in the air (yield 70 - 91%). Elemental analysis data 
and melting points were carried out, their results are summarized in Table 1. 
25 
 
3.3.3 Synthesis of [PtL4Cl2] complexes 
As mentioned above for selone ligands instability in air [PtL4]Cl2 complexes were 
prepared by same method earlier with varying the ratio  by dissolved (1mmol) of selone 
ligands in methanol solvent added to (0.25mmol) of Potassium tetracholoropaltinate(II) 
which dissolved in a hot acetonitrile. Then the mixture solutions were stirred for 1hour 
under nitrogen in a dry box using anhydrous deairated solvents, colored solution were 
observed. Then solutions were filtered and the solvents were evaporated and the products 
were obtained and finally they were recrystallized with methanol and the desired 
compounds were obtained by yields from 60–90%.  All the analytical data and melting 
points of these complexes were summarized in Table 2.  
Table 1: Elemental analyses and melting points (◦C) of [PtL2Cl2] complexes. 
  Complex 
Found (Calcd.) (%) Melting 
point (
◦
C) 
Color Yield % 
C H N 
A1 (DiazSe)2PtCl2 
16.22 2.72 9.46 
183-186 Orange 76.45 
(15.96) (2.58) (9.04) 
A2 (DiapSe)2PtCl2 
19.36 3.25 9.03 
215-218 Brown 85.56 
(20.18) (3.43) (8.78) 
A3 (PrIMSe)2PtCl2 
22.23 3.73 8.64 
161-163 Brown 78.87 
(22.75) (3.87) (8.98) 
A4 (SeU)2PtCl2 
4.69 1.57 10.94 
191-192 Black 69.74 
(4.72) (1.39) (10.56) 
A5 (EtIMSe)2PtCl2 
19.36 3.25 9.03 
195-198 Yellow 81.98 
(19.85) (3.38) (9.20) 
A6 (IMSe)2PtCl2 
12.77 2.14 9.93 
226-229 Yellow 91.28 
(12.89) (2.27) (10.19) 
A7 (i-PrIMSe)2PtCl2 
22.23 3.73 8.64 
178 Brown 66.81 
(22.05) (3.54) (8.73) 
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Table 2: Elemental analysis and melting points (◦C) of [PtL4]Cl2 complexes. 
  Complex 
Found (Calcd.) (%) Melting 
point (
◦
C) 
Color Yield % 
C H N 
B1 (DiazSe)4PtCl2 
20.92 3.51 12.20 
250 Orange 65.68 
(20.76) (3.58) (12.14) 
B2 (DiapSe)4PtCl2 
24.65 4.13 11.49 
301-304 Green 76.5 
(23.78) (4.02) (10.97) 
B3 (PrIMSe)4PtCl2 
27.97 4.69 10.87 
119-122 
Golden 
Yellow 
83.16 
(25.90) (4.42) (10.02) 
B4 (SeU)4PtCl2 
6.33 2.12 14.78 
195-197 Yellow 64.65 
(5.98) (2.07) (13.98) 
B5 (EtIMSe)4PtCl2 
24.65 4.13 11.49 
215 
Yellowish 
Green 
90.82 
(23.97) (4.08) (11.23) 
B6 (IMSe)4PtCl2 
16.71 2.80 12.99 
219-221 Yellow 85.81 
(16.87) (2.86) (12.68) 
B7 (i-PrIMSe)4PtCl2 
27.97 4.69 10.87 
173-176 Orange 81.16 
(27.05) (4.57) (10.33) 
 
3.4 Single crystal X-ray crystallography 
 
X- Ray measurements of B5 and B7 were obtained as yellow plates by methanol. The 
data were performed at 203K (-70°C) and 293(20°C) respectively on a Stoe Mark II-
Image Plate Diffraction System [102] equipped by goniometer of two-circle and using 
monochromated radiation (λ = 0.71073 Å) MoKα graphite. Molecular structures were 
obtained using SHELXS-2014 [103]. The all calculations and refinement were achieved 
usingSHELXL-2014 [104].  
The C-bound H-atoms and NH were calculated and treated as riding atoms: C-H = 0.97 - 
0.98 Å with Uiso(H) = 1.5Ueq(C) for methyl H atoms and = 1.2Ueq(C) for other H-atoms. 
While the non-H atoms were refined anisotropically using full-matrix least-squares on 
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F2. A semi-empirical absorption correction was applied using the MULABS routine in 
PLATON [105]. The figures were drawn using the program Mercury [106]. 
The whole molecules of the B5 and B7 compounds are generated by inversion symmetry, 
with the Pt(II) ion located at inversion center of the complex. 
Table 3: Summary of crystallographic data for complexes for B5. 
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Table 4: Summary of crystallographic data for complexes for B7. 
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3.5 In vitro cytotoxic activity against HeLa and MCF7 human cancer 
cell lines 
3.5.1 Cell cultures 
Human Cervical cancer  HeLa and Brest  cancer cell lines MCF-7 were grown in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% Fetal Bovine 
Serum (FBS), and 1% penicillin (10,000 units), streptomycin (10 mg), in 74 cm2 flask 
and incubated until 80% confluences obtained in humidified environment of, 5% CO2, 
95% air, 37 °C. 
3.5.2 MTT assays for anticancer activity of [PtL2Cl2] complexes 
All [PtL2Cl2] complexes and cisplatin (positive control) at 0.195 μM, 0.39μM, 0.781μM, 
1.56μM, 3.125 μM, 6.25 μM, 12.5 μM, 25 μM, and 50 μM concentrations were prepared 
in DMEM. Cancer cells were seeded and maintained in quadruplicate in a 96-well tissue 
culture plate at 5 X 104 cells per well in 200 μl of same medium. The cancer cells were 
incubated 24 hours before the treatment. All compounds were dissolved in 50% DMSO. 
Therefore, DMSO was used as a negative control. The final DMSO concentration, in 
each well, was less than 0.1%. The cancer cells were treated with the synthesized 
compounds along with the cisplatin and the resultant cultures were incubated for 24 h. 
The medium of wells was discarded and 100 µL DMEM containing MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (5 mg/mL) was added to the 
wells and incubated in a CO2 incubator at 37 °C in the dark for 4 hrs. After incubation, a 
purple colored formazan (artificial chromogenic dye, a product of the reduction of water 
insoluble tetrazolium salts e.g., MTT by dehydrogenases and reductases) in the cells is 
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produced and appeared as dark crystals in the bottom of the wells. The medium of culture 
was discarded from each well carefully to avoid disruption of the monolayer. Around 100 
µL of isopropanol has been added in each well. To dissolve the formazan crystals the 
solution was mixed in the wells which gave a purple solution. Using Mithras2LB943 
against reagent blank, the absorbance of the 96-well plate was taken at 570 nm. All data 
presented are mean ± standard deviation. 
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CHAPTER 4 
RESULTS AND DISCUSSIONS 
 
4.1 Synthesis of the compounds 
The interaction of  platinum(II)  with selone ligands gave  two types of compounds with a 
general formula of [PtCl2(L)2] and ionic species of [Pt(L)4]Cl2  in a good yields with 
different melting points see Table 1 and 2.  
The two types of complexes were synthesized by direct addition of a solution of 
potassium tetracchloroplatinate(II) K2PtCl4  to aqueous solution of the selenium 
containing ligands. The first series of these complexes have been synthesized in molar 
ratio 1:2 (0.500 mmol) of K2PtCl4 with (1.00 mmol) of selone ligands resulted in a clear 
colored solutions,colored precipitate complexes were obtained directly after sterring. 
These compounds are expected to have trans-configurations based on stereochemical 
aspects. 
The elemental analyses data of the [PtCl2(L)2] complexes were summarized in Table 1.  
And the second series of complexes have been synthesized in molar ratio 1:4 when an 
aqueous solutions of K2PtCl4 (0.25 mmol) was treated with selenium containing ligands 
(selone ligands) (1.00 mmol) such as isopropyl-IMSe (B7) and ethyl-IMSe (B5) resulted 
in the form of a yellow clear solution.  After the mixture was left at ambient temperature, 
the resultant yellow crystals appropriate for X-ray structure determination were recovered 
after solvent mixtures were evaporated. While the other selone ligands gave powder 
products when they are treated with K2PtCl4, the observed elemental analytical data 
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(CHNS) % of ionic species of [Pt(L)4]Cl2  compounds is consistent with their 
compositions as given in Table 2. 
4.2 Spectral measurements 
4.2.1 Infrared Spectroscopy  
The ambidentate selenium containing ligands (selones) are potentially capable to interact 
through the selenium or the nitrogen atoms. There are three major infrared bands that are 
generally diagnose the particular binding mode of selones to platinum(II) ions. These 
include ν(>C=Se), ν(C- N) and ν(N–H) [40]. All the selected infrared spectroscopic 
absorption frequencies of the selenium containing ligands (selones) and their related 
platinum(II) species are listed in Table 5. The assignment of selenocarbonyl(>C=Se) 
frequencies for the all of the platinum(II) compounds with selone ligands is difficult in 
the infrared spectra, this is attributed to the strongest coupling between 
selenocarbonyl(>C=Se) band with various absorptions signal in the region of fingerprint 
in FTIR spectrum.  However, the characteristic band in the range from (500-650 cm
-1
) 
directly assigned for (>C=Se) vibrations [107].   A shift in ν(>C=Se) mode of all free 
selone ligands towards lower frequencies is observed on its complexation with 
platinum(II). This shifting of bands towards lower wave number in most platinum(II) 
complexes, is in agreement with our suggestion that selenium atom is bonded to platinum 
center and the double bond character has been reduced,and this confirms that the selone 
ligand coordinate to the platinum(II) ion through selenium of selenocarbonyl group [107].   
The strong and broad band in the range of 1400-1600 cm
−1
 was observed for all free 
selones and their corresponding compounds. According to the literature, this band 
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assigned for (C- N) stretching vibrations. Upon the coordination this signal shifted to 
higher frequency (wave number), this is indicating to an increase in the number of # 
electron density of C-N bond because of the connection via selenium [107-108]. 
The characteristic band in the spectrum of the free selone near 3200 cm
−1
 was observed 
and assigned directly to N–H stretching vibrations. This band is shifted to a higher 
frequency in all the synthesized platinum (II) compounds as a result of increase in the 
double bond character of  C-N and this confirms  that the selone ligand coordinate to the 
platinum(II) ion through selenium  of selencarbonyl group not via nitrogen atom [109]. 
The existence of (N–H) vibration mode in the compounds after the complexation 
confirms the presence of solid state selone ligands in our new complexes [110]. 
The far-infrared spectra in the frequency region below 400 cm
-1
 has been done to 
investigate v(M-Se) and  v(M-Cl) stretching frequencies,  which lie in the  range of about 
300 cm
-1
 for the transition-metal complexes according to literature [111]. In all 
complexes a sharp peak around 270 cm
-1
 was observed and assigned to platinum- 
seleinum bond. In case of the first series another peak around 300 cm
-1
 were observed 
and assigned for Pt-Cl bond [111].  
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Table 5: Selected  mid and far infrared absorption (cm
−1
) of the selones and their 
corresponding complexes. 
Code Species 
Mid and Far-IR frequencies (cm
−1
) 
ν(C=Se) ν(C-N) ν(N–H) ν(Pt–Se) ν(Pt-Cl) 
- DiazSe 601 1430 3200 - - 
A1 (DiazSe)2PtCl2 561 1469 3267 262 326 
B1 (DiazSe)4PtCl2 587 1473 3285 268 - 
- DiapSe 615 1453 3224 - - 
A2 (DaipSe)2PtCl2 510 1459 3350 265 331 
B2 (DaipSe)4PtCl2 606 1549 3386 274 - 
- PrImSe 513 1460 3210 - - 
A3 (PrImSe)2PtCl2 492 1497 3343 275 321 
B3 (PrImSe)4PtCl2 501 1510 3390 281 - 
- SeU 736 1520 3265 - - 
A4 (SeU)2PtCl2 560 1565 3267 263 328 
B4 (SeU)4PtCl2 586 1609 3310 271 - 
- EtIMSe 514 1465 3198 - - 
A5 (Et-ImSe)2PtCl2 479 1479 3265 273 332 
B5 (Et-ImSe)4PtCl2 574 1505 3106 287 - 
- ImSe 561 1463 3250 - - 
A6 (ImSe)2PtCl2 513 1499 3325 268 327 
B6 (ImSe)4PtCl2 566 1520 3369 272 - 
- i-PrImSe 601 1453 3210 - - 
A7 (i-PrImSe)2PtCl2 556 1486 3267 273 334 
B7 (i-PrImSe)4PtCl2 598 1532 3304 281 - 
 
4.2.2 
1
H NMR  
All the 
1
H NMR spectra of the two types of synthesized complexes of general formula of 
[PtCl2(L)2] and ionic species of [Pt(L)4]Cl2  have been measured in DMSO d6 solution, 
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and all of the synthesized compounds shows the expected signals and all the signal 
assigned to the free selenium containing ligands(selones) observed In the  
1
H NMR 
spectra were also observed in the synthesized complexes spectra. 
1
H NMR data for the synthesized compounds and their original free ligands are listed in 
Table 6 (numbering of ligands in Figure 2). The N-H resonance shift of selone ligands, 
are observed after coordination to Pt(II) ion. However, this signal upon coordination to 
platinum metal becomes less intensity and shifted slightly downfield toward higher 
frequency by the range from 0.86 ppm at A5 complex to 1.6 ppm at B7 compound from 
their positions in the free ligands. These shifts are due to the move of the electron density 
from the group of selenocarbonyl to the neighboring N-C bond [108]. This increasing of 
electron density shift for the double bond character of C-N single bond while reducing, 
the double bond character of the >C=Se, resulting in a downfield shift for the N-H 
resonance [110,112]. This downfield shift is characteristic of the free selones bounded to 
Pt(II) ion  via the selenium atoms not through atoms of nitrogen  [113-114]. These NMR 
shifts upon coordination are consistent with platinum binding stabilizing, the resonance 
structure formula that describes the places of the positive charge into the heterocyclic 
ring which are schemed in Figure 12. 
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Figure 12: Resonances structures for the selone ligands. 
4.2.3 
13
C NMR  
All the 
13
C {
1
H} NMR chemical shifts for free selone ligand and their corresponding 
platinum complexes are summarized in Table 6. 
13
C {
1
H}NMR spectroscopy of Pt(II) with selone ligands compounds. For all of the 
platinum compounds, the 
13
C {
1
H} NMR resonances for the selenocarbonyl(>C=Se) of 
the platinum bound selenium containing ligands (selones) are shifted upfield relative to 
uncoordinated ligands, and this shows a good consistent with that reported by the 
literature [111].  
This  upfield shift is assigned for the C-2 resonance corresponding to selenocarbonyl 
>C=Se resonance observed in lower frequency regions by the range from 2.75 ppm at B5 
to  13.97 ppm at A6 specie as compared to the free selone ligands.  
These shifts are due to the decreasing in the double bond character of the >C=Se and 
formation of partial double bond character in the C-N bond. This confirms the suggestion 
that selones ligands are coordinated to the Pt(II) ion via selenium of selenocarbonyl not 
through nitrogen atom [ 112 ,115]. 
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The increased of # electron density for the C-N bond upon coordination to platinum metal 
results in negligible increases in deshielding effects on C-4 and C-5, as supported by 
observed downfield shifts of the C-4 and C-5 resonances directly [116]. 
Table 6:
1
H and 
13
C{
1
H} NMR chemical shifts in ppm for the Pt(II) compounds with 
selones in DMSO d6. 
Code Species N-H C-2 C-4 C-5 C-6 C-7 N-C1 N-C2 CH3 
 
DiazSe 8.07 169.07 40.36 18.88 40.36 - - - - 
A1 (DiazSe)2PtCl2 9.30 160.48 40.26 18.46 40.26 - - - - 
  ∆ 1.23 -8.59 -0.10 -0.42 -0.10 - - - - 
B1 (DiazSe)4PtCl2 9.08 162.13 40.15 18.86 40.15 - - - - 
  ∆  1.01 -6.94 -0.21 -0.02 -0.21 - - - - 
 
DiapSe 8.07 180.83 45.5 26.86 26.86 45.5 - - - 
A2 (DaipSe)2PtCl2 9.16 171.71 46.78 26.4 26.4 46.78 - - - 
  ∆ 1.09 -9.12 1.28 -0.46 -0.46 1.28 - - - 
B2 (DaipSe)4PtCl2 9.19 171.88 46.64 26.25 26.25 46.64 - - - 
  ∆  1.12 -8.95 1.14 -0.61 -0.61 1.14 - - - 
 
PrImSe 8.81
b
 179.55
a
 50.19 48.62 - - 42.60 20.37 10.99 
A3 (PrImSe)2PtCl2 9.85 176.65 52.21 49.85 - - 43.27 21.32 11.21 
  ∆ 1.04 -2.90 2.02 1.23 - - 0.67 0.95 0.22 
B3 (PrImSe)4PtCl2 9.66 170.42 49.82 49.59 - - 43.82 20.76 11.1 
  ∆  0.85 -9.13 -0.37 0.97 - - 1.22 0.39 0.11 
 
SeU 7.59 178.83 - - - - - - - 
A4 (SeU)2PtCl2 8.59 168.02 - - - - - - - 
  ∆ 1.00 -10.83 - - - - - - - 
B4 (SeU)4PtCl2 8.55 171.19 - - - - - - - 
  ∆  0.96 -7.64 - - - - - - - 
 
Et-ImSe 8.32 178.66 43.33 47.91 - - 42.51 - 12.09 
A5 (Et-ImSe)2PtCl2 9.15 174.59 43 48.38 - - 42.9 - 12.19 
  ∆  0.83 -4.07 -0.33 0.47 - - 0.39 - 0.10 
B5 (Et-ImSe)4PtCl2 9.67 175.91 43.18 48.96 - - 43.18 - 12.23 
  ∆   1.35 -2.75 -0.15 1.05 - - 0.67 - 0.14 
 
ImSe 8.32 177.05 45.26 45.26 - - - - - 
A6 (ImSe)2PtCl2 9.47 163.08 45.64 45.64 - - - - - 
  ∆  1.15 -13.97 0.38 0.38 - - - - - 
B6 (ImSe)4PtCl2 9.59 167.93 45.34 45.34 - - - - - 
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  ∆   1.27 -9.12 0.08 0.08 - - - - - 
 
i -PrImSe 8.26 177.71 42.65 42.69 - - 48.21 - 19.45 
A7 (i-PrImSe)2PtCl2 9.44 167.47 44.00 43.58 - - 48.35 - 19.65 
  ∆  1.18 -10.24 1.35 0.89 - - 0.14 - 0.20 
B7 (i-PrImSe)4PtCl2 9.86 167.3 43.13 43.69 - - 48.92 - 19.41 
  ∆   1.60 -10.41 0.48 1.00 - - 0.71 - -0.04 
a
  Dissolved in D2O. 
b
 Dissolved in CDCl3. ∆ = Change in chemical shifts. 
4.2.4 
13
C solid state NMR  
Table 7, lists all the significant 
13
C solid state NMR signals of the selones and their 
relevant platinum(II) compounds. In solid state 
13
C NMR, no significant change in the 
chemical shifts of the selones ligand after coordination were observed other than C-2 
signals see Table 7. Upfield shifts of 5.70 to 14.88 ppm in           resonance indicates that 
in all compounds, platinum(II) ion is coordinated to selenium containing ligands 
(selones) via selenium not through nitrogen atom [115-116]. 
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Table 7: Shows the solid state 
13
C NMR chemical shifts of Pt(II) complexes with selones. 
Code Species C-2 C-4 C-5 C-6 C-7 N-C1 –CH3 
 DiazSe 171.07 40.36 19.55 40.36 - - - 
A1 (DiazSe)2PtCl2 162.25 40.26 18.98 40.26 - - - 
B1 (DiazSe)4PtCl2 166.54 40.15 19.25 40.15 - - - 
 DaipSe 183.08 48.62 27.21 27.21 48.62 - - 
A2 (DaipSe)2PtCl2 168.2 45.75 27.8 27.8 45.75 - - 
B2 (DaipSe)4PtCl2 174.79 48.47 28.38 28.38 48.47 - - 
 SeU 178.21 - - - - - - 
A4 (SeU)2PtCl2 167.91 - - - - - - 
B4 (SeU)4PtCl2 172.51 - - - - - - 
 Et-ImSe 177.02 43.33 47.91 - 42.51 - 12.09 
A5 (Et-ImSe)2PtCl2 166.23 43.11 48.38 - 42.92 - 12.19 
B5 (Et-ImSe)4PtCl2 168.11 43.18 48.96 - 43.18 - 12.23 
 ImSe 176.38 45.91 45.91 - - - - 
A6 (ImSe)2PtCl2 166.41 41.29 19.23 - - - - 
B6 (ImSe)4PtCl2 168.38 42.39 20.96 - - - - 
4.2.5 
77
Se{
1
H} NMR  
77
Se NMR measurements were reported relative to (NaHSeO3 in D2O) as external 
reference at 1308.00 ppm, using 95.35 MHz, 2.00 s pulse delay and using 0.311 s 
acquisition time. 
The 
77
Se{
1
H} solution NMR spectra for all of the synthesized platinum(II)  complexes 
with selone ligands have been carried out in DMSO-d6 as they are given in Table 8.  
In all Pt(II) complexes, the >C=Se signal shifted upfield in the range between (δ -4.38 for 
complex B7  to -76.25 at complex A2) upon the selenium containg ligands(selones) 
coordinated to platinum central atom relative to their free selone ligands.  
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This upfield shift due to the binding of selenium atom to electron-rich site of Platinum 
ion.  However, there is no correlation exists between the lengths of (Pt-Se bond) and 
77
Se 
NMR shifts. Also this shift related to an increasing in π e density in of N-C bond after 
coordination took place [117].  This very large shielding provides a clear evidence for 
selenium binding to platinum (II) ion not to nitrogen atom [115,117]. 
4.2.6 
195
Pt  NMR  
All our synthesized platinum(II) complexes containing selone ligands and their precursor 
potassium tetracholoplatinate (K2PtCl4  with ẟ = -1620 ppm in D2O) have been tested 
using 
195
Pt NMR solution in CD3OD as NMR solvent and all of them their platinum 
signals shifted to upfield after the complexation due to highest shielding occurred by the 
movement of the electrons from the selenium atom of the selone ligands to the central 
platinum atom of these complexes through covenant bond, these upfield shifts confirmed 
the suggestion that the Pt(II) ion connected to the free selone ligands through the 
selenium atom only  [118-119]. And all their data listed in Table 8. 
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Table 8: 
77
Se{
1
H} and  
195
Pt NMR data in ppm for the platinum(II) compounds with 
selones in DMSO d6 . 
Code  Species ẟ 77Se in ppm a ẟ 195Pt in ppm b 
 DiazSe 199.93 - 
A1 (DiazSe)2PtCl2 126.35 - 3950 
 ∆ -73.58 2330 
B1 (DiazSe)4PtCl2 176.69 - 4220 
 ∆ -23.24 - 2600 
 DaipSe 292.00 - 
A2 (DaipSe)2PtCl2 215.75 - 3934 
 ∆ -76.25 2314 
B2 (DaipSe)4PtCl2 273.78 - 4318 
 ∆ -18.22 2698 
 N-PrImSe 57.93 - 
A3 (N-PrImSe)2PtCl2 26.91 - 3875 
 ∆ -31.02 2255 
B3 (N-PrImSe)4PtCl2 43.70 -4327 
 ∆ -14.23 2707 
 (SeU) 200.70 - 
A4 (SeU)2PtCl2 149.60 N/A 
 ∆ -51.12 - 
B4 (SeU)4PtCl2 172.84 N/A 
 ∆ -27.88 - 
 EtImse 64.85 - 
A5 (EtImse)2PtCl2 47.35 - 3975 
 ∆ -17.50 2355 
B5 (EtImse)4PtCl2 57.23  -4315 
 ∆ -7.62 2695 
 ImSe 73.53 - 
A6 (ImSe)2PtCl2 48.52 N/A 
 ∆ -25.01 - 
B6 (ImSe)4PtCl2 60.61 N/A 
 ∆ -12.92 - 
 i-PrImSe 69.29 - 
A7 (i-PrImSe)2PtCl2 29.50 - 3810 
 ∆ -39.79 2190 
B7 (i-PrImSe)4PtCl2 64.91 - 4317 
 ∆ -4.38 2697 
a
 in DMSO and  
b 
in CD3OD 
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4.3 Structural analysis of tetrakis-platinum(II) selone complexes 
4.3.1 Crystal structure of complex B5 and B7 
The X-ray structure of compounds B5 and B7 are shown in Figures 13 and 15 
respectively. The geometrical parameters are given in Table 9. The Pt
2+
 ion in both B5 
and B7 is coordinated to four selenium atoms, each belonging to an N-
alkylimidazolidine-2-selenone ligand. The Pt–Se bond lengths of 2.4200(11)–2.4389(7) 
Å are similar to the related compounds [46, 67] such as, tetrakis(selenourea)platinum(II) 
chloride [61]. In B5, the cis Se–Pt–Se angles are 86.98(3) and 93.02(3)°, while the trans 
angles are 180°. In B7, the cis angles around Pt are nearly 90°, whereas the trans angles 
are 165.64(4)° and 173.49(4)° (Table 9). These values reflect that the geometry at 
platinum is somewhat distorted square planar.  The SeCN2 moieties of the ligand 
molecules are essentially planar. The smaller N–C(Se) bond lengths compared to the 
otherN–C bond distances are in agreement with a marked double bond character in the 
N–C(Se) bond.  In B5, the N–H groups (N1-H1 and N3–H3) of two cis selenone ligands 
are engaged in hydrogen bonding with a common chloride ion giving a hydrogen bonding 
bridge [N–H⋯Cl⋯H–N] as shown in Figure 14. A closer look to hydrogen bonding 
interactions in B7 reveals that all the selenone ligands are engaged in hydrogen bonding 
interactions with one chloride counter ion resulting in an umbrella like structure as shown 
in Figure 16. This H-bonding scheme gives two decametallacycles 
[PtSeCNH⋯Cl⋯HNCS] in which all the selenium atoms are pushed out of the [PtSe4] 
mean plane. The details of hydrogen-bond geometry (Å, °) in B5 and B7 are given in 
Tables 10 and 11 respectively.  
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Figure 13: A view of the molecular structure of B5, with atom labelling. The 
displacement ellipsoids are drawn at the 50% probability level. The unlabeled atoms are 
related to the labelled atoms by symmetry code: -x + 1, -y + 1, -z + 1. 
 
 
Figure 14: The packing of the crystal B5, observed along the (a) axis. The N-H…Cl, C-
H…Cl and C-H…Se hydrogen bonds (dashed lines) lead to the formation of a three-
dimensional supramolecular structure. 
44 
 
 
Figure 15: A view of the molecular structure of B7, with atom labelling. The 
displacement ellipsoids are drawn at the 50% probability level. The unlabeled atoms are 
related to the labelled atoms by symmetry code: -x + 1, -y + 1, -z + 1. 
 
Figure 16: The packing of the crystal B7, observed along the (a) axis. The N-H…Cl and 
C-H…Cl hydrogen bonds (dashed lines). 
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Table 9: Selected bond distances (Å) and bond angles (˚) for compound B5 and B7. 
B5 
Pt1-Se1 2.4320(7) Se1-Pt1-Se2 93.02(3) 
Pt1-Se2 2.4389(7) Se1a-Pt1-Se2a 93.02(3) 
Se1-C1  Se1-Pt1-Se2a 86.98(3) 
N1-C1  Se1a-Pt1-Se2 86.98(3) 
N1-C2  Se1-Pt1-Se1a 180.00 
  Se2-Pt1-Se2a 180.00) 
B7    
Pt1-Se1 2.4278(11) Se1-Pt1-Se2 89.48(4) 
Pt1-Se2 2.4216(11) Se1-Pt1-Se3 89.64(4) 
Pt1-Se1 2.4200(11) Se1-Pt1-Se4 165.64(4) 
Pt1-Se1 2.4305(11) Se2-Pt1-Se3 173.49(4) 
  Se2-Pt1-Se4 90.05(4) 
  Se3-Pt1-Se4 89.20(4) 
Symmetry code for 1, a = 1-x,1-y,1-z 
 
 
 
 
 
46 
 
Table 10: Hydrogen-bond geometry (Å, °) for B5. 
 
Table 11: Hydrogen-bond geometry (Å, °) for B7 
D—H···A D—H H···A D···A D—H···A 
N8—HN8···Cl1i 0.86 2.46 3.266 (9) 155.8 
N6—HN6···Cl1i 0.86 2.43 3.262 (10) 163.5 
N2—HN2···Cl1i 0.86 2.45 3.244 (10) 154.6 
N4—H4A···Cl1i 0.86 2.5 3.284 (11) 152.3 
C20—H20A···Cl2A 0.97 2.95 3.616 (16) 126.7 
C23—H23C···Cl2B 0.96 2.92 3.882 (18) 177 
C23—H23A···Se4ii 0.96 3.19 3.810 (14) 123.7 
C21—H21A···Cl2Bi 0.97 2.76 3.541 (18) 137.6 
C16—H16···Se3 0.98 2.79 3.287 (11) 111.8 
C16—H16···Se3iii 0.98 3.17 3.819 (12) 125.4 
C10—H10···Se2 0.98 2.72 3.279 (11) 116.9 
C10—H10···Se2 0.98 2.72 3.279 (11) 116.9 
C16—H16···Se3 0.98 2.79 3.287 (11) 111.8 
C16—H16···Se3iii 0.98 3.17 3.819 (12) 125.4 
C20—H20A···Cl2A 0.97 2.95 3.616 (16) 126.7 
C21—H21A···Cl2Bi 0.97 2.76 3.541 (18) 137.6 
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C23—H23C···Cl2B 0.96 2.92 3.882 (18) 177 
N2—HN2···Cl1i 0.86 2.45 3.244 (10) 154.6 
N4—H4A···Cl1i 0.86 2.5 3.284 (11) 152.3 
N6—HN6···Cl1i 0.86 2.43 3.262 (10) 163.5 
N8—HN8···Cl1i 0.86 2.46 3.266 (9) 155.8 
Symmetry codes: (i) x, −y+1/2, z+1/2; (ii) −x+1, −y, −z+1; (iii) −x+1, −y, −z+2. 
 
 
4.4 In vitro cytotoxicity of [PtL2Cl2] complexes 
The cytotoxicity of synthesized complexes A1, A2, A3, A4, A5, A6, A7 and cisplatin 
were assessed against two human cancers cell lines such as MCF7 (human breast cancer) 
and HeLa (human cervical cancer) cell lines. The cells were brooded with the studied 
compounds for 24 h and the feasibility was evaluated by a conventional MTT test. The 
IC50 values of the synthesized compounds and cisplatin for MCF7 and HeLa human 
cancer cell lines were collected from the curves of the cell percentage viability and the 
concentration of the compound [120].  Furthermore, the impact of PtL2Cl2 complexes in 
μM on the percentage feasibility % of HeLa and MCF7 human cancer cells has been 
indicated graphically in figures 16 and 17 respectively. The IC50 values of synthesized 
compounds run between 8.30 – 25.74 µM as given in Table 14. 
Table 14, showed the effect of the A1, A2, A3, A4, A5, A6 and A7 complexes on HeLa 
(human cervical cancer) cell line, the IC50 values for these compounds ranged from 11.33 
to 25.74 μM indicates that the synthesized complexes are better in vitro cytotoxic agents 
than that of cisplatin, except compound A6 was recognized to be less cytotoxic than 
cisplatin with IC50 value of 25.74 µM, while the IC50 value of cisplatin is of is 21.40 μM. 
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On the other hand, the result showed the complexes A1-A6 are two times higher 
cytotoxicity than cisplatin.  
The synthesized complexes were also examined against (human breast cancer) MCF7 cell 
line; the compounds A5, A6 and A7 were showed more cytotoxic than cisplatin. 
However, the in vitro cytotoxicity of compounds A1-A4 against MCF7cell lines was 
found to be less than cisplatin. 
 On the other hand, the observed results of these synthesized compounds A1-A7 have 
consistent with a significant discerning cytotoxicity against specific human cancer cell 
lines and these complexes have high ability to interact with biomolecules such as proteins 
and DNA through ligand exchange. 
Table 12: The potential cytotoxicity of the synthesized complexes A1–A7 and cisplatin 
given as IC50 ± S.D. in μM. 
 
Code Complexes 
IC50 ± SEM
a
 
HeLa MCF7 
- Cisplatin 21.40 ± 0.73 8.98 ± 0.07 
A1 (DiazSe)2PtCl2 11.33 ± 0.20 12.27 ± 0.01 
A2 (DaipSe)2PtCl2 11.50 ± 0.22 16.68 ± 0.02 
A3 (N-PrImSe)2PtCl2 12.89 ± 0.16 18.64 ± 0.03 
A4 (SeU)2PtCl2 19.78 ± 0.13 11.11 ± 0.05 
A5 (EtImse)2PtCl2 17.73 ± 0.14 8.59 ± 0.07 
A6 (ImSe)2PtCl2 25.74 ± 0.19 8.11 ± 0.06 
A7 (i-PrImSe)2PtCl2 14.03 ± 0.16 8.30 ± 0.06 
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Figure 17: Effect of concentration in μM of [PtL2Cl2] complexes and cisplatin on the 
percentage of cell viability of HeLa. 
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Figure 18: Effect of concentration in μM of [PtL2Cl2] complexes and cisplatin on the 
percentage of cell viability of MCF7. 
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CHAPTER 5 
CONCLUSION AND RECOMMENDATIONS 
5.1 Conclusion 
 
Biologically active Pt
2+
 selone complexes have been synthesized and characterized using 
both spectroscopic and analytical techniques and their anticancer activity has been 
studied and compared to cisplatin. The X-ray measurements for compounds 
[Pt(etimse)4][Cl2] (B5) and  [Pt(isoprimse)4][Cl2] (B7) have been determined. The data 
indicated that the platinum(II) ions were surrounded  by the selone ligands via their 
selenium atoms and not via nitrogen atoms and the four-coordinate selone complexes of  
B5 and B7 adopt distorted square planar geometry. 
The anticancer potential of the synthesized complexes was evaluated against HeLa and 
MCF7 human cancer cell lines. Most of the synthesized complexes showed higher 
cytotoxicity than cisplatin, and as it is clear in Table 14, A1 complex have shown the 
highest cytotoxicity in HeLa cancer cell more than two fold better than cisplatin and the 
A6 complex is best one in the treatment of the breast cancer. These finding could be the 
subject of further pharmacological investigations. 
5.2 Recommendations 
 
For future work, we highly recommend to study the interaction of the synthesized 
complexes with DNA, to explore the electronic effect of the ligands as well as to 
investigate the in vivo cytotoxicity of these complexes. 
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Appendix A. 
1
H NMR 
 
1
H chemical shifts (ppm) of DiazSe and its Pt(II) complexes[A1 and B1] in DMSO-d6 
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1
H chemical shifts (ppm) of DiapSe and its Pt(II) complexes[A 2 and B2] in DMSO-d6 
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1
H chemical shifts (ppm) of IMSe and its Pt(II) complexes[A6 and B6] in DMSO-d6. 
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Appendix B. 
13
C NMR 
 
13
C chemical shifts (ppm) of DiazSe and its Pt(II) complexes[A1 and B1] in D2O. 
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13
C chemical shifts (ppm) of DiapSe and its Pt(II) complexes[A 2 and B2] in D2O. 
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13
C chemical shifts (ppm) of IMSe and its Pt(II) complexes[A6 and B6] in DMSO-d6. 
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Appendix C. 
77
Se NMR 
 
77
Se chemical shifts (ppm) of SeU and its Pt(II) complexes[ 
 
 
 
 
 
 
 
 
 
77
Se chemical shifts (ppm) of SeU and its Pt(II) complexes[A4 and B4] in DMSO-d6. 
 
SeU 
A4 
B4 
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77
Se chemical shifts (ppm) of DiapSe and its Pt(II) complexes[A2 and B2] in DMSO-d6. 
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Appendix D. 
195
Pt NMR 
 
195
Pt chemical shifts (ppm) of K2PtCl4 and its Pt(II) complexes[A2and B2] in DMSO-d6.
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